SANOFI news, videos and press releases - Page 4
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
- Availability of the Q4 2021 Memorandum for modelling purposes
- Sanofi: Information concerning the total number of voting rights and shares - NOVEMBER 2021
- Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
- Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
- New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
- Sanofi: Information concerning the total number of voting rights and shares - October 2021
- Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
- Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)
- Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
- Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
- New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021
- Sanofi: Information concerning the total number of voting rights and shares - August 2021
- Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
- Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics
- Sanofi to acquire Kadmon to further strengthen growth of transplant business
- Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
- Sanofi: Information concerning the total number of voting rights and shares - July 2021
- Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients
- Sanofi: Information concerning the total number of voting rights and shares - June 2021
- Sanofi: Information concerning the total number of voting rights and shares - May 2021
- Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
- Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
- European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
- New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
- Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
- Sanofi provides update on venglustat clinical program
- Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
- Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
- Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research